Novascan is real-time Ex vivo point of touch cancer detection.
Novascan is the first and only company to identify a single parameter, the Cole Relaxation Frequency, that is several orders
of magnitude different for cancerous and noncancerous tissue
Cells hold an electrical charge and as cancer develops, begin to leak that charge.
Using the CRF system the Novascan Canary has the potential to detect that leakage, converting it to a digital signal that can be analyzed quantitatively.
The software has been proven in various clinical studies to accurately detect the presence of cancer in tissue samples without any destructive impact on the sample itself.
Novascan Detection Electrodes
The Novascan detection electrodes can be fabricated to less than 1mm in size and can be outfitted to accept fine needle biopsy samples or those from traditional forceps
NovaScan’s Leadership
NovaScan’s leadership believes that improving the detection and stratification of cancer – be it in initial detection of cancer, during a procedure, or in post-procedural pathology – can improve patient outcomes, increase physician economics, and reduce the cost of care.
